Literature DB >> 29206621

Human Vaccines & Immunotherapeutics: News.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29206621      PMCID: PMC5718783          DOI: 10.1080/21645515.2017.1409572

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  7 in total

1.  Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Authors:  V Gopalakrishnan; C N Spencer; L Nezi; A Reuben; M C Andrews; T V Karpinets; P A Prieto; D Vicente; K Hoffman; S C Wei; A P Cogdill; L Zhao; C W Hudgens; D S Hutchinson; T Manzo; M Petaccia de Macedo; T Cotechini; T Kumar; W S Chen; S M Reddy; R Szczepaniak Sloane; J Galloway-Pena; H Jiang; P L Chen; E J Shpall; K Rezvani; A M Alousi; R F Chemaly; S Shelburne; L M Vence; P C Okhuysen; V B Jensen; A G Swennes; F McAllister; E Marcelo Riquelme Sanchez; Y Zhang; E Le Chatelier; L Zitvogel; N Pons; J L Austin-Breneman; L E Haydu; E M Burton; J M Gardner; E Sirmans; J Hu; A J Lazar; T Tsujikawa; A Diab; H Tawbi; I C Glitza; W J Hwu; S P Patel; S E Woodman; R N Amaria; M A Davies; J E Gershenwald; P Hwu; J E Lee; J Zhang; L M Coussens; Z A Cooper; P A Futreal; C R Daniel; N J Ajami; J F Petrosino; M T Tetzlaff; P Sharma; J P Allison; R R Jenq; J A Wargo
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

2.  Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Authors:  Bertrand Routy; Emmanuelle Le Chatelier; Lisa Derosa; Connie P M Duong; Maryam Tidjani Alou; Romain Daillère; Aurélie Fluckiger; Meriem Messaoudene; Conrad Rauber; Maria P Roberti; Marine Fidelle; Caroline Flament; Vichnou Poirier-Colame; Paule Opolon; Christophe Klein; Kristina Iribarren; Laura Mondragón; Nicolas Jacquelot; Bo Qu; Gladys Ferrere; Céline Clémenson; Laura Mezquita; Jordi Remon Masip; Charles Naltet; Solenn Brosseau; Coureche Kaderbhai; Corentin Richard; Hira Rizvi; Florence Levenez; Nathalie Galleron; Benoit Quinquis; Nicolas Pons; Bernhard Ryffel; Véronique Minard-Colin; Patrick Gonin; Jean-Charles Soria; Eric Deutsch; Yohann Loriot; François Ghiringhelli; Gérard Zalcman; François Goldwasser; Bernard Escudier; Matthew D Hellmann; Alexander Eggermont; Didier Raoult; Laurence Albiges; Guido Kroemer; Laurence Zitvogel
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

3.  Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report.

Authors:  Pablo Tebas; Christine C Roberts; Kar Muthumani; Emma L Reuschel; Sagar B Kudchodkar; Faraz I Zaidi; Scott White; Amir S Khan; Trina Racine; Hyeree Choi; Jean Boyer; Young K Park; Sylvie Trottier; Celine Remigio; Diane Krieger; Susan E Spruill; Mark Bagarazzi; Gary P Kobinger; David B Weiner; Joel N Maslow
Journal:  N Engl J Med       Date:  2017-10-04       Impact factor: 91.245

4.  Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.

Authors:  Stephen B Kennedy; Fatorma Bolay; Mark Kieh; Greg Grandits; Moses Badio; Ripley Ballou; Risa Eckes; Mark Feinberg; Dean Follmann; Birgit Grund; Swati Gupta; Lisa Hensley; Elizabeth Higgs; Krisztina Janosko; Melvin Johnson; Francis Kateh; James Logue; Jonathan Marchand; Thomas Monath; Martha Nason; Tolbert Nyenswah; François Roman; Eric Stavale; Julian Wolfson; James D Neaton; H Clifford Lane
Journal:  N Engl J Med       Date:  2017-10-12       Impact factor: 91.245

5.  Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Authors:  Warner K Huh; Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Rosires Pereira de Andrade; Kevin A Ault; Deborah Bartholomew; Ramon M Cestero; Edison N Fedrizzi; Angelica L Hirschberg; Marie-Hélène Mayrand; Angela Maria Ruiz-Sternberg; Jack T Stapleton; Dorothy J Wiley; Alex Ferenczy; Robert Kurman; Brigitte M Ronnett; Mark H Stoler; Jack Cuzick; Suzanne M Garland; Susanne K Kjaer; Oliver M Bautista; Richard Haupt; Erin Moeller; Michael Ritter; Christine C Roberts; Christine Shields; Alain Luxembourg
Journal:  Lancet       Date:  2017-09-05       Impact factor: 79.321

6.  Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.

Authors:  Celina Jin; Malick M Gibani; Maria Moore; Helene B Juel; Elizabeth Jones; James Meiring; Victoria Harris; Jonathan Gardner; Anna Nebykova; Simon A Kerridge; Jennifer Hill; Helena Thomaides-Brears; Christoph J Blohmke; Ly-Mee Yu; Brian Angus; Andrew J Pollard
Journal:  Lancet       Date:  2017-09-28       Impact factor: 79.321

7.  Comprehensive vaccine design for commensal disease progression.

Authors:  Charles H Jones; Guojian Zhang; Roozbeh Nayerhoda; Marie Beitelshees; Andrew Hill; Pooya Rostami; Yi Li; Bruce A Davidson; Paul Knight; Blaine A Pfeifer
Journal:  Sci Adv       Date:  2017-10-18       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.